Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/AKT2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/AKT2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AKT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AKT2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AKT2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AKT2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AKT2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00442821 | Colorectum | SER | small molecule catabolic process | 87/2897 | 376/18723 | 5.31e-05 | 1.27e-03 | 87 |
GO:00709971 | Colorectum | SER | neuron death | 84/2897 | 361/18723 | 5.76e-05 | 1.35e-03 | 84 |
GO:00328681 | Colorectum | SER | response to insulin | 65/2897 | 264/18723 | 6.70e-05 | 1.53e-03 | 65 |
GO:00090621 | Colorectum | SER | fatty acid catabolic process | 31/2897 | 100/18723 | 7.09e-05 | 1.61e-03 | 31 |
GO:19016531 | Colorectum | SER | cellular response to peptide | 83/2897 | 359/18723 | 8.03e-05 | 1.77e-03 | 83 |
GO:00434341 | Colorectum | SER | response to peptide hormone | 93/2897 | 414/18723 | 9.61e-05 | 2.04e-03 | 93 |
GO:00514021 | Colorectum | SER | neuron apoptotic process | 60/2897 | 246/18723 | 1.65e-04 | 3.13e-03 | 60 |
GO:00066351 | Colorectum | SER | fatty acid beta-oxidation | 24/2897 | 74/18723 | 2.09e-04 | 3.77e-03 | 24 |
GO:00713751 | Colorectum | SER | cellular response to peptide hormone stimulus | 68/2897 | 290/18723 | 2.20e-04 | 3.89e-03 | 68 |
GO:00328691 | Colorectum | SER | cellular response to insulin stimulus | 51/2897 | 203/18723 | 2.30e-04 | 3.96e-03 | 51 |
GO:00611801 | Colorectum | SER | mammary gland epithelium development | 22/2897 | 67/18723 | 3.11e-04 | 5.03e-03 | 22 |
GO:00723291 | Colorectum | SER | monocarboxylic acid catabolic process | 34/2897 | 122/18723 | 3.27e-04 | 5.22e-03 | 34 |
GO:00160501 | Colorectum | SER | vesicle organization | 69/2897 | 300/18723 | 3.59e-04 | 5.61e-03 | 69 |
GO:00308791 | Colorectum | SER | mammary gland development | 37/2897 | 137/18723 | 3.61e-04 | 5.61e-03 | 37 |
GO:00064171 | Colorectum | SER | regulation of translation | 100/2897 | 468/18723 | 3.76e-04 | 5.74e-03 | 100 |
GO:00430871 | Colorectum | SER | regulation of GTPase activity | 77/2897 | 348/18723 | 5.90e-04 | 8.07e-03 | 77 |
GO:00193181 | Colorectum | SER | hexose metabolic process | 56/2897 | 237/18723 | 6.19e-04 | 8.42e-03 | 56 |
GO:00193951 | Colorectum | SER | fatty acid oxidation | 29/2897 | 103/18723 | 7.24e-04 | 9.44e-03 | 29 |
GO:00442421 | Colorectum | SER | cellular lipid catabolic process | 51/2897 | 214/18723 | 8.60e-04 | 1.05e-02 | 51 |
GO:19035331 | Colorectum | SER | regulation of protein targeting | 24/2897 | 81/18723 | 9.20e-04 | 1.11e-02 | 24 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa05017 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05213 | Colorectum | AD | Endometrial cancer | 29/2092 | 58/8465 | 2.69e-05 | 2.57e-04 | 1.64e-04 | 29 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa04213 | Colorectum | AD | Longevity regulating pathway - multiple species | 27/2092 | 62/8465 | 8.72e-04 | 5.96e-03 | 3.80e-03 | 27 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL2177390 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | GDC-0068 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 405560349 | | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | TRICIRIBINE | TRICIRIBINE | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 223366042 | CAPIVASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL3545134 | LY-2780301 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 249565578 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | AFURESERTIB HYDROCHLORIDE | | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 249565628 | MK-2206 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | MK2206 | MK-2206 | |